Combining CD38 and CD73 inhibition synergistically could be a strategy to overcome resistance from the microvesicles released after treating with an anti‐CD38 agent, particularly since the CD38 pathway is more active in MM. This evidence concerns the gene CD38 and Miyoshi myopathy.